REFERENCES
- Olsen CM. Consensus Statements. Applying structure. J Am Med Assoc 1995;273:72–3
- Consensus Development Meeting: Metabolic aspects of oral contraceptives of relevance for cardiovascular diseases. Am J Obstet Gynecol 1990;162:1335–7
- Consensus Development Meeting: Combined oral contraceptives and cardiovascular diseases. Gynecol Endo- crinol 1996;10:1–5
- Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:805–13
- Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcome during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). J Am Med Assoc 2002;288:49–57
- Writing Group for the Women´s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women´s Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33